Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

Status unconfirmed · Early Phase 1

Conditions studied: Non Small Cell Lung Cancer

In brief

This is a pilot study looking at using stereotactic radiosurgery and full dose chemotherapy to treat stage II and III lung cancer that is not amendable to surgical resection.

Key facts

Study ID

NCT02568033

Run by

The Cooper Health System

People needed

22

Starts

2013-10-01

Expected to finish

2017-10-01

Last updated by the study team

2017-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Nonsmall cell lung cancer (NSCLC) (any histology)
• unresectable stage II
• Stage III
• Tumor less than 8 cm
• Karnofsky performance scale (KPS) of 50 or better
• Three or fewer mediastinal or hilar lymph nodes

You may not qualify if…

• Small cell lung cancer (SCLC)
• Stage I and stage IV patients
• Stage II patients eligible for surgical resection
• Concurrent severe disease that the treating physician feels will interfere with therapy this can include significant cardiovascular or pulmonary disease.
• KPS 40 or less (bed bound)
• Tumor size greater than 8 cm
• Inability to safely treat target lesions (at discretion of treating physician, this would most likely be secondary to not being able to place fiducial markers for tracking)
• Four or more medisatinal or hilar lymph nodes

Where it is running

• MD Anderson Cancer Center at Cooper — Camden, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.